Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GI Blood Loss with REGN9933 or REGN7508 vs Rivaroxaban + Aspirin
NCT06444178Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Sep 2024
- Primary completion
- Apr 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of amrecibart and REGN7508 in venous thromboembolism (VTE) and Atrial fibrillation (AFib) (4 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Change in fecal hemoglobin content at Day 22. Started Sep 2024; status: completed.
02
Drugs
amrecibartREGN7508
03
Conditions
venous thromboembolism (VTE)Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT06444178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06444178.